BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER Drug Patent Profile
When do Bacteriostatic Sodium Chloride 0.9% In Plastic Container patents expire, and when can generic versions of Bacteriostatic Sodium Chloride 0.9% In Plastic Container launch?
Bacteriostatic Sodium Chloride 0.9% In Plastic Container is a drug marketed by Abraxis Pharm, Fresenius Kabi Usa, and Hospira. and is included in three NDAs.
The generic ingredient in BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is sodium chloride. There is one drug master file entry for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the sodium chloride profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER?
- What are the global sales for BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER?
- What is Average Wholesale Price for BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER?
Summary for BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
| US Patents: | 0 |
| Applicants: | 3 |
| NDAs: | 3 |
| Finished Product Suppliers / Packagers: | 6 |
| Raw Ingredient (Bulk) Api Vendors: | 142 |
| Clinical Trials: | 60 |
| DailyMed Link: | BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER at DailyMed |
Recent Clinical Trials for BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Plymouth | EARLY_PHASE1 |
| National University Hospital, Singapore | PHASE2 |
| National Medical Research Council (NMRC), Singapore | PHASE2 |
See all BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER clinical trials
Pharmacology for BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
| Drug Class | Osmotic Laxative |
| Mechanism of Action | Osmotic Activity |
| Physiological Effect | Increased Large Intestinal Motility Inhibition Large Intestine Fluid/Electrolyte Absorption |

